Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 355

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

DEXAMETHASONE INTRAVITREAL IMPLANT FOR TREATMENT OF DIABETIC MACULAR EDEMA IN VITRECTOMIZED PATIENTS

Boyer, David S, Faber, David, Gupta, Sunil, Patel, Sunil S, Tabandeh, Homayoun, Li, Xiao-Yan, Liu, Charlie C, Lou, Jean, Whitcup, Scott M·2011·Retina

Abstract

In Brief Purpose: To evaluate the safety and efficacy of Ozurdex (dexamethasone intravitreal implant) 0.7 mg in the treatment of diabetic macular edema in vitrectomized eyes. Methods: This was a prospective, multicenter, open-label, 26-week study. Fifty-five patients with treatment-resistant diabetic macular edema and a history of previous pars plana vitrectomy in the study eye received a single intravitreal injection of 0.7-mg dexamethasone intravitreal implant. The primary efficacy outcome measure was the change in central retinal thickness from baseline to Week 26 measured by optical coherence tomography. Results: The mean age of patients was 62 years. The mean duration of diabetic macular edema was 43 months. The mean (95% confidence interval) change from baseline central retinal thickness (403 μm) was −156 μm (−190, −122 μm) at Week 8 (P < 0.001) and −39 μm (−65, −13 μm) at Week 26 (P = 0.004). The mean (95% CI) increase in best-corrected visual acuity from baseline (54.5 letters) was 6.0 letters (3.9, 8.1 letters) at Week 8 (P < 0.001) and 3.0 letters (0.1, 6.0 letters) at Week 26 (P = 0.046). At Week 8, 30.4% of patients had gained ≥10 letters in best-corrected visual acuity. Conjunctival hemorrhage, conjunctival hyperemia, eye pain, and increased intraocular pressure were the most common adverse events. Conclusion: Treatment with dexamethasone intravitreal implant led to statistically and clinically significant improvements in both vision and vascular leakage from diabetic macular edema in difficult-to-treat vitrectomized eyes and had an acceptable safety profile. A 26-week, open-label study evaluated the safety and efficacy of a sustained-release dexamethasone intravitreal implant for treatment of diabetic macular edema in eyes with previous vitrectomy. Dexamethasone intravitreal implant had an acceptable safety profile and effectively reduced central retinal thickness and improved visual acuity in difficult-to-treat vitrectomized eyes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/iae.0b013e318206d18c

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 355

Metadata

Authors
Boyer, D. S., Faber, D., Gupta, S., Patel, S. S., Tabandeh, H., Li, X.-Y., Liu, C. C., Lou, J., & Whitcup, S. M.
Venue
Retina
Published
2011-05
Volume
31
Issue
5
Pages
915-923
ISSN
0275-004X (ISSN-L)
OpenAlex
W1965020544
Cited by
355
References
16
FWCI
26.88
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: DEXAMETHASONE INTRAVITREAL IMPLANT FOR TREATMENT OF DIABETIC MACULAR EDEMA IN VITRECTOMIZED PATIENTS. https://app.cochat.ai/papers/10.1097/iae.0b013e318206d18c
The paper
Boyer, D. S., Faber, D., Gupta, S., Patel, S. S., Tabandeh, H., Li, X.-Y., Liu, C. C., Lou, J., & Whitcup, S. M. (2011). DEXAMETHASONE INTRAVITREAL IMPLANT FOR TREATMENT OF DIABETIC MACULAR EDEMA IN VITRECTOMIZED PATIENTS. Retina. https://doi.org/10.1097/iae.0b013e318206d18c

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.